Search

Author/Creator Lala, Mallika

1. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. (May 2020)

Authors:
Lala, Mallika; Li, Tommy Ruosi; de Alwis, Dinesh P.; Sinha, Vikram; Mayawala, Kapil; Yamamoto, Noboru; Siu, Lillian L.; Chartash, Elliot; Aboshady, Hesham; Jain, Lokesh
Journal:
European journal of cancer
Issue:
Volume 131(2020)
Page Start:
68
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68–75]. (February 2021)

Authors:
Lala, Mallika; Li, Tommy Ruosi; de Alwis, Dinesh P.; Sinha, Vikram; Mayawala, Kapil; Li, Mengyao; Yamamoto, Noboru; Siu, Lillian L.; Chartash, Elliot; Aboshady, Hesham; Jain, Lokesh
Journal:
European journal of cancer
Issue:
Volume 144(2021)
Page Start:
400
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Immunogenicity of pembrolizumab in patients with advanced tumors. Issue 1 (8th August 2019)

Authors:
van Vugt, Marianne J. H.; Stone, Julie A.; De Greef, "Rik" H. J. M. M.; Snyder, Ellen S.; Lipka, Leslie; Turner, David C.; Chain, Anne; Lala, Mallika; Li, Mengyao; Robey, Seth H.; Kondic, Anna G.; De Alwis, Dinesh; Mayawala, Kapil; Jain, Lokesh; Freshwater, Tomoko
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 7:Issue 1(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin. Issue 5 (23rd January 2020)

Authors:
Bhagunde, Pratik; Colon‐Gonzalez, Francheska; Liu, Yang; Wu, Jin; Xu, Shiyao Sherrie; Garrett, Graigory; Jumes, Patricia; Lasseter, Kenneth; Marbury, Thomas; Rizk, Matthew L.; Lala, Mallika; Rhee, Elizabeth G.; Butterton, Joan R.; Boundy, Keith
Journal:
British journal of clinical pharmacology
Issue:
Volume 86:Issue 5(2020)
Page Start:
944
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. (1st April 2016)

Authors:
van Hasselt, J. G. Coen; Rizk, Matthew L.; Lala, Mallika; Chavez‐Eng, Cynthia; Visser, Sandra A. G.; Kerbusch, Thomas; Danhof, Meindert; Rao, Gauri; van der Graaf, Piet H.
Journal:
British journal of clinical pharmacology
Issue:
Volume 81:Number 6(2016:Jun.)
Page Start:
1113
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections. (4th October 2019)

Authors:
Bhagunde, Pratik; Patel, Parul; Lala, Mallika; Watson, Kenny; Copalu, William; Xu, Ming; Kulkarni, Pooja; Young, Katherine; Rizk, Matthew L.
Journal:
CPT: pharmacometrics & systems pharmacology
Issue:
Volume 8:Number 10(2019)
Page Start:
748
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants. Issue 4 (25th March 2020)

Authors:
Boundy, Keith; Liu, Yang; Bhagunde, Pratik; O'Reilly, Terry E.; Colon‐Gonzalez, Francheska; Friedman, Evan J.; Lala, Mallika; Rhee, Elizabeth G.; Rizk, Matthew L.
Journal:
Clinical pharmacology in drug development
Issue:
Volume 9:Issue 4(2020)
Page Start:
466
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗